Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Focal Prostate Ablation Combined With ADT for Prostate Cancer
NCT05790213Phase 2Recruiting
- Sponsor
- University of Chicago
- Start
- May 2025
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in prostate cancer (PCa), sponsored by University of Chicago. Primary endpoints: Number of participants with clinically significant residual prostate cancer in ablated prostate tissue, Number of participants with clinically significant residual prostate cancer in unablated prostate tissue and 1 more. Started May 2025; status: recruiting.
02
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05790213.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05790213.